[go: up one dir, main page]

FR2884425B3 - Composition pharmaceutique destinee a soigner le psoriasis - Google Patents

Composition pharmaceutique destinee a soigner le psoriasis

Info

Publication number
FR2884425B3
FR2884425B3 FR0503827A FR0503827A FR2884425B3 FR 2884425 B3 FR2884425 B3 FR 2884425B3 FR 0503827 A FR0503827 A FR 0503827A FR 0503827 A FR0503827 A FR 0503827A FR 2884425 B3 FR2884425 B3 FR 2884425B3
Authority
FR
France
Prior art keywords
pharmaceutical composition
treating psoriasis
marine
composition
given
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0503827A
Other languages
English (en)
Other versions
FR2884425A1 (fr
Inventor
Paul Robert Francois Dupont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0503827A priority Critical patent/FR2884425B3/fr
Priority to FR0506496A priority patent/FR2884423B1/fr
Priority to PL06743672T priority patent/PL1871399T3/pl
Priority to CA2606255A priority patent/CA2606255C/fr
Priority to ES06743672T priority patent/ES2359987T3/es
Priority to DE602006019842T priority patent/DE602006019842D1/de
Priority to US11/911,743 priority patent/US7759325B2/en
Priority to AT06743672T priority patent/ATE496628T1/de
Priority to EP06743672A priority patent/EP1871399B1/fr
Priority to PCT/FR2006/000792 priority patent/WO2006111633A2/fr
Publication of FR2884425A1 publication Critical patent/FR2884425A1/fr
Application granted granted Critical
Publication of FR2884425B3 publication Critical patent/FR2884425B3/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composition pharmaceutique destinée à traiter le psoriasisl'invention a pour objet l'utilisation dans une composition, ou pour la préparation d'une telle composition, d'une quantité efficace de lécithine marine riche en phospholipides pour soigner le psoriasis.le terme lécithine marine riche en phospholipides doit s'entendre par un produit obtenu par extraction d'une source marine, soit des poissons, du phytoplancton, du zooplancton, du Krill et crevettes polaires, des crustacés ou encore des algues marines et dont la composition renferme des phospholipides dont la phosphatidylcholine, le phosphatidyl inositol, la phosphatidyl sérine ou la sphingomyéline.La présente invention est donc à la disposition d'un laboratoire pharmaceutique en vue de la fabrication d'un médicament pour le psoriasis.
FR0503827A 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis Expired - Lifetime FR2884425B3 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0503827A FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis
FR0506496A FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
CA2606255A CA2606255C (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
ES06743672T ES2359987T3 (es) 2005-04-18 2006-04-11 Utilización de la lecitina como medicamento en el tratamiento de la soriasis.
DE602006019842T DE602006019842D1 (de) 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
US11/911,743 US7759325B2 (en) 2005-04-18 2006-04-11 Use of lecithin as a medication for the treatment of psoriasis
PL06743672T PL1871399T3 (pl) 2005-04-18 2006-04-11 Zastosowanie lecytyny jako leku w leczeniu łuszczycy
AT06743672T ATE496628T1 (de) 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
EP06743672A EP1871399B1 (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
PCT/FR2006/000792 WO2006111633A2 (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0503827A FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis

Publications (2)

Publication Number Publication Date
FR2884425A1 FR2884425A1 (fr) 2006-10-20
FR2884425B3 true FR2884425B3 (fr) 2007-05-25

Family

ID=35463696

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0503827A Expired - Lifetime FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis
FR0506496A Expired - Fee Related FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR0506496A Expired - Fee Related FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Country Status (4)

Country Link
AT (1) ATE496628T1 (fr)
DE (1) DE602006019842D1 (fr)
ES (1) ES2359987T3 (fr)
FR (2) FR2884425B3 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108004016A (zh) * 2017-12-18 2018-05-08 青岛康境海洋生物科技有限公司 一种高卵磷脂含量的南极磷虾油的制备方法
CN113995763B (zh) * 2021-11-10 2023-08-11 中南大学湘雅医院 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042348A1 (fr) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Composition hydratante topique et methode associee
US20020012648A1 (en) * 1998-02-06 2002-01-31 Orthoefer Frank T. High phospholipid-containing dermatological compositions
WO2005002591A1 (fr) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Traitement du psoriasis, de l'impetigo, de la teigne par lipositol, cephaline et lecithine

Also Published As

Publication number Publication date
FR2884423A1 (fr) 2006-10-20
ATE496628T1 (de) 2011-02-15
DE602006019842D1 (de) 2011-03-10
FR2884423B1 (fr) 2007-06-22
FR2884425A1 (fr) 2006-10-20
ES2359987T3 (es) 2011-05-30

Similar Documents

Publication Publication Date Title
WO2009050506A3 (fr) Combinaison 059
BRPI0512796A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
DE502007003850D1 (de) Gel zur Behandlung von Wunden
ATE495728T1 (de) Kosmetische oder dermatologische zubereitungen mit n-acetylcystein
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE418965T1 (de) Medikamentöse gezielte lokale lipolyse
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
FR2884425B3 (fr) Composition pharmaceutique destinee a soigner le psoriasis
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
BRPI0507321A (pt) derivados de 7-amino-4-quinolona-3-ácido carboxìlico substituìdos com cicloalquila, processos para produção dos mesmos e uso dos mesmos como medicamento
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
EA200702026A1 (ru) Лечение или предупреждение зуда
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
EA201070478A1 (ru) Дифенилкарбоновые кислоты и их производные
BRPI0514193A (pt) agente de diminuição de crp, método para previnir e/ou tratar uma doença envolvida em elevação de crp, e, uso de um composto tendo uma atividade inibitória de esqualeno sintase, ou uma pró-droga do mesmo, ou um sal do mesmo
BR0317925A (pt) Utilização de uma molécula ativa, composição cosmética e processo de tratamento da celulite

Legal Events

Date Code Title Description
TP Transmission of property